Creative-Diagnostics) SARS-CoV-2 Indian Variant B.1.617 RBD (E484Q/L452R)
작성자
abbabio
작성일자
2021-05-31
조회수
384
Available Now: SARS-CoV-2 Indian Variant B.1.617 RBD (E484Q/L452R)
Some emerging SARS-CoV-2 variants, such as the U.K. variant B.1.1.7, Brazil variant P.1, South Africa variant B.1.351, and India variant B.1.617, are spreading rapidly and causing concerns. These variants can evade neutralizing antibodies induced by previous infection or vaccination through mutations in the spike protein, including the receptor-binding domain (RBD).
Several studies have shown that mutations identified in the RBD domain of the spike protein, such as L452R (CD Cat # DAGC376), E484Q (CD Cat # DAGC585) present in B.1.617, and E484K (CD Cat # DAGC507) present in B.1.351 and P.1 lineages, might allow evasion from neutralizing antibodies.
Creative Diagnostics has developed a panel of recombinant RBD/Spike protein variants carrying the aforementioned mutations:
Recombinant Mutants from the India Variant | B.1.617
Creative Diagnostics now can provide SARS-CoV-2 Spike/RBD Mutants which were expressed in HEK293 cells. Antigens are post-translationally modified (glycosylation and phosphorylation) and more closely resembling the native viral proteins that can overcome specificity issues in COVID-19 serology assays.
The SARS-CoV-2 spike CHO-K1 cell line has been developed by the stable transfection of the SARS-CoV-2 spike protein plasmid. SARS-CoV-2 spike CHO-K1 cell line provides consistent levels of __expression__ of the SARS-CoV-2 spike protein on the cell surface.
To understand the cell entry mechanisms of SARS-CoV-2, it is essential to study how Spike proteins interact with the ACE2 receptor. To avoid the danger of producing and manipulating live coronavirus, live SARS-CoV-2 needs to be handled under biosafety level 3 conditions.
